MedTrace Logo

Effect of Glucosamine or Ibuprofen Combined With Physical Training in Patients With Knee-Osteoarthritis

NCT00833157 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2009-01-30

No results posted yet for this study

Summary

The investigators will investigate the effect of glucosamine or ibuprofen combined with 12 weeks of muscle strength-training in patients with knee-osteoarthritis.

The investigators would like to elucidate whether treatment with glucosamine or NSAID interact with the effects of exercise in osteoarthritis patients.

Conditions

  • Osteoarthritis of the Knee

Interventions

DRUG

glucosamine sulphate

Subjects are administered glucosamine-sulphate tablets of 500 mg \* 3 daily, while they are performing a strength-training program with both legs (\*3 weekly) for 12 weeks.

DRUG

ibuprofen

Subjects are administered 600 mg \* 2 daily, while they are performing a strength-training program with both legs (\*3 weekly) for 12 weeks

DRUG

placebo

Subjects are administered placebo tablets, while they are performing a strength-training program (\*3 weekly) with both legs for 12 weeks

Sponsors & Collaborators

  • Lund University

    collaborator OTHER

  • The Danish Rheumatism Association

    collaborator OTHER

  • Ministry of the Interior and Health, Denmark

    collaborator OTHER_GOV

  • Bispebjerg Hospital

    lead OTHER

Principal Investigators

  • Susanne G Petersen, MD · Bispebjerg Hospital, Institute of Sports Medicine Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2007-07-31
Completion
2009-03-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00833157 on ClinicalTrials.gov